Kolexia
Avet-Loiseau Herve Pédiatrie
Avet-Loiseau Herve
Pédiatrie
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
545 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Maladie résiduelle Récidive tumorale locale Aberrations des chromosomes Translocation génétique Leucémies Myélome multiple indolent Délétion de segment de chromosome

Collaborateurs

Voir plus
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Attal Michel
Attal Michel
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Facon Thierry
Facon Thierry
Hôpital Huriez, Lille, France
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France

Industries

Voir plus
Abbvie
10 collaboration(s)
Dernière en 2023
Sanofi
10 collaboration(s)
Dernière en 2022
Roche
10 collaboration(s)
Dernière en 2023
Janssen
7 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma
Essai Clinique (Janssen)   11 mars 2024
Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier.
Leukemia   09 mars 2024
Early CAR-T Cells expansion is associated with prolonged PFS for patients with RRMM treated with ide-cel: a retrospective monocentric study.
Transplantation and cellular therapy   06 mars 2024
Smoldering Multiple Myeloma : Taking the narrow over the wide path?
Blood   01 mars 2024
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Essai Clinique (Janssen)   27 février 2024
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma: A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Essai Clinique (Janssen)   27 février 2024
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Essai Clinique (Janssen)   27 février 2024
Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma.
Blood   23 février 2024
Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses.
Cell reports   17 janvier 2024
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.
Frontiers in oncology   04 décembre 2023